Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO Sells $480,750.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO John Todd Koning sold 37,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total transaction of $480,750.00. Following the completion of the sale, the chief financial officer now owns 393,356 shares in the company, valued at $5,042,823.92. The transaction was disclosed in a document filed with the SEC, which is available at this link.

John Todd Koning also recently made the following trade(s):

• On Friday, March 1st, John Todd Koning sold 121,601 shares of Alphatec stock. The shares were sold at an average price of $13.30, for a total transaction of $1,617,293.30.

Alphatec Trading Up 1.6 %

Shares of NASDAQ ATEC traded up $0.20 during midday trading on Friday, reaching $12.44. The stock had a trading volume of 1,255,900 shares, compared to its average volume of 1,614,278. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -7.90 and a beta of 1.55. Alphatec Holdings, Inc. has a twelve month low of $8.66 and a twelve month high of $19.14. The company has a debt-to-equity ratio of 6.54, a quick ratio of 1.99 and a current ratio of 2.86. The company’s 50 day moving average price is $13.69 and its 200 day moving average price is $13.46.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). The firm had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $131.90 million. The business’s revenue for the quarter was up 30.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.33) EPS. As a group, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.1 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on ATEC. Wells Fargo & Company began coverage on shares of Alphatec in a research note on Friday, February 9th. They issued an “overweight” rating and a $26.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Monday, March 4th. Needham & Company LLC raised their price target on shares of Alphatec from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Alphatec in a report on Wednesday, March 20th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, Alphatec currently has an average rating of “Moderate Buy” and an average target price of $23.63.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ATEC. Amalgamated Bank lifted its position in shares of Alphatec by 7.3% during the 4th quarter. Amalgamated Bank now owns 9,720 shares of the medical technology company’s stock valued at $147,000 after acquiring an additional 660 shares during the period. Valeo Financial Advisors LLC lifted its position in shares of Alphatec by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 19,025 shares of the medical technology company’s stock valued at $287,000 after acquiring an additional 900 shares during the period. RiverPark Advisors LLC increased its stake in Alphatec by 22.6% during the 4th quarter. RiverPark Advisors LLC now owns 5,033 shares of the medical technology company’s stock valued at $76,000 after purchasing an additional 928 shares in the last quarter. Handelsbanken Fonder AB increased its stake in Alphatec by 5.0% during the 4th quarter. Handelsbanken Fonder AB now owns 20,900 shares of the medical technology company’s stock valued at $316,000 after purchasing an additional 1,000 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in Alphatec by 4.7% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 22,904 shares of the medical technology company’s stock valued at $297,000 after purchasing an additional 1,030 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.